

transportation and infrastructure sectors, has not only scaled up its India business, but transformed it from a supply chain centre into an R&D hub serving both domestic and global markets. Industry digitalisation is the new area where ABB could tap into India's expertise and potential, said Ulrich Spiesshofer, its CEO, in an interview with BusinessLine.

Digitalisation is a new theme for ABB globally. How are Indian operations supporting this new shift and what are some of the innovations

products and tried to sell them in India, then we localised manufacturing, and now, we have a strong R&D capability here that helps us and drives product development, offering solutions both for India and abroad.

ABB India has a very strong engineering capability for utilities and we have transformed the role over the last five years making it a real corporate global centre of R&D.

In industrial automation, we focus on control and the software side, we also have a strong cybersecurity team here. In the

crucial role in driving it forward.

On the transport and infrastructure side, we have got rail solutions here that we are continuously developing. We are also working here on building automation capabilities.

**Can India become a significant export hub for ABB? What are the challenges?**

Altogether, the Indian



we are at 15 per cent, but there is more to come.

Historically, the biggest challenge was to have predictable, reliable product quality coming out of Indian manufacturer-

have with South-East Asia is helping. So today, we are at a much better position to drive exports.

**How big is the digitalisation opportunity in India and what are the challenges in its**

**The biggest challenge was to have predictable, reliable product quality coming out of Indian manufacturing. Our team has solved this challenge.**

**ULRICH SPIESSHOFER**  
CEO, ABB

we would have a growth opportunity of \$20 billion for ABB altogether.

Given that India is a place where digitalisation is something that is pretty much in the DNA of people's thinking, that we have industries here like ICT and finance that have already progressed in digitalisation, we have a country very open to the opportunities in digitalisation.

**Are you planning any new investments in India to support this growth?**

In the last couple of years, we

ABB India as an export centre; and thirdly, to strengthen ABB India's role in the context of the global ABB.

Today, we have 47 manufacturing facilities, and 22 service centres, out of which the vast part is going to the digital space, so it is not about adding more locations, but adding more content and people in these locations.

We are continuously hiring; we have 11,000 people today, while when I started at ABB it was just 3,000 people.

Renewable energy sources are kicking in, and there will be more feeling points, longer distances, more volatility, less predictability, what a wonderful opportunity to create value as a key technology player.

If you look at the end of the electricity value chain – on the demand side – there is electric mobility coming to the masses, data centres coming in, smart cities, all of this requires technology for electrification. So, the underlying growth pattern of our portfolio is very strong.

## IIL bags ₹210-cr govt order to supply 5-in-one vaccine

**M SOMASEKHAR**

Hyderabad, May 28

Indian Immunologicals Ltd (IIL) has bagged a ₹210-crore order from the government to supply 140 million doses of the 5-in-one pentavalent vaccine that it has developed indigenously.

The Hyderabad-based IIL, a subsidiary of the National Dairy Development Board (NDDB), launched Vaxtar 5, its pentavalent vaccine for children a couple of months ago.

The company bagged the order against stiff competition and pipped Serum Institute of Pune. IIL will supply over the next two years for the government's universal immunisation programme, said K Anand Kumar, Managing Director.

Developed with the company's research and development expertise, it will be made at the IIL's vaccine manufacturing facility in Hyderabad for the retail market as well as the Health Ministry's Immunisation Programme.

Vaxtar 5, which offers

its portfolio into human vaccines as well. The company has five manufacturing plants – four across the country and one in New Zealand.

**Nipah virus**

Asked about the prospects of controlling the sudden outbreak of the virus in Kerala and a report from Karnataka, Anand Kumar said that it could hopefully be a small incident and localised. Earlier, reports of its incidence in Siliguri, Bangladesh, and origins in Malaysia have had varying impact.

The best way to tackle the Nipah virus spread was to adhere to care and containment, improve sanitation and protection measures for the next few weeks. It is not possible to develop a vaccine given the wide range of bacterial and viral infections, Anand Kumar added.

This is the first big contract after obtaining the production licence for IIL, which is a leading producer of animal health vaccines, and has diversified

IIL will supply Vaxtar 5 over the next two years for the government's universal immunisation programme

protection against Diphteria, Pertussis, Tetanus, Hepatitis B and Hib, has been tested in multiple centres under prescribed government guidelines. The vaccine is available in single and multi-dose formats.

The Ministry, which had introduced the pentavalent vaccine four years ago into the Universal Immunisation Programme that aims to cover maximum number of children with all the essential vaccines, procures 85-90 million doses annually, and is in the process of scaling up the use across the country.

The IIL has recently tied up with the Griffith University, Australia, to work on the Ebola virus and a possible development of a vaccine in the long-term.

## DALMIA BHARAT SUGAR AND INDUSTRIES LIMITED



Regd. Office : Dalmiapuram - 621 651, Distt. Tiruchirapalli (Tamil Nadu)  
Phone : 011 23465100, Fax (011) 23313303

Email : [invhelp@dalmiasugar.com](mailto:invhelp@dalmiasugar.com) . Website : [www.dalmiasugar.com](http://www.dalmiasugar.com) . CIN : L26942TN1951PLC000640  
Extract of Audited Financial Results for the Quarter/Financial Year ended 31-03-2018  
(₹ Lakhs)

S.No.	Particulars	Standalone			Standalone		Consolidated	
		For the Quarter ended			For the Financial Year ended		For the Financial Year ended	
		31-03-18	31-12-17	31-03-17	31-03-18	31-03-17	31-03-18	31-03-17
1	Total Income from Operations	49,230	61,148	45,395	2,30,825	1,78,795	2,29,606	1,78,793
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items.)	(3,415)	7,202	6,344	14,787	24,409	13,618	24,358
3	Net Profit/ (Loss) for the period-before Tax (After Exceptional and/or Extraordinary items.)	(3,415)	7,202	6,344	14,787	24,409	13,618	24,358
4	Net Profit/ (Loss) for the period after Tax (After Exceptional and/or Extraordinary items.)	(1,256)	5,424	3,911	13,410	18,677	12,230	18,626
5	Total Comprehensive Income for the period [comprising profit/(Loss) for the period (after tax) and other comprehensive income (after tax)]	(4,260)	11,342	9,693	21,839	29,578	26,261	29,989
6	Equity Share Capital	1,619	1,619	1,619	1,619	1,619	1,619	1,619
7	Earning per Share (of ₹ 2 each)	(1.55)	6.70	4.83	16.57	23.08	15.11	23.01
a)	Basic							
b)	Diluted							

### Notes :-

- The results have been reviewed by the audit committee and approved by the Board of Directors in their meeting held on May 28, 2018.
- Post the applicability of Goods and Service Tax (GST) with effect from 1 July 2017, revenue from operations are disclosed net of GST. Accordingly, the revenue from operations and excise duty expenses for the quarter and period ended 31st March 2018 are not comparable with the previous periods presented in the results.
- The above is the extract of the detailed format of quarterly/yearly financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/yearly financial results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company website [www.dalmiasugar.com](http://www.dalmiasugar.com).

For Dalmia Bharat Sugar and Industries Limited

J. S. Baijal  
Chairman

Place: New Delhi  
Date: May 28, 2018

ELGI

